Mackenzie Financial
TVTX icon

Mackenzie Financial’s Travere Therapeutics TVTX Stock Holding History

Mackenzie Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
75,603
+34,213
+83% +$1.02M ﹤0.01% 900
2025
Q4 		$1.56M Sell
41,390
-8,980
-18% -$292K ﹤0.01% 941
2025
Q3 		$1.2M Sell
50,370
-9,933
-16% -$187K ﹤0.01% 1017
2025
Q2 		$892K Buy
+60,303
New +$1,000K ﹤0.01% 1041

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mackenzie Financial's TVTX Position: Q1 2026 in Review

Mackenzie Financial increased its Travere Therapeutics (TVTX) stake by 83% in Q1 2026, buying an estimated $1.02M and bringing the position to 75,603 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #900.

Mackenzie Financial first reported a position in TVTX in Q2 2025 and has held it in 4 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Mackenzie Financial held 75,603 shares of Travere Therapeutics worth $2.25M as of Q1 2026.
  • Mackenzie Financial bought 34,213 Travere Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Travere Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q1 2026, its #900 holding.
  • Mackenzie Financial first reported a position in Travere Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.